JPMorgan upgraded UCB to Overweight from Neutral with a price target of EUR 200, up from EUR 150. The analyst expects an expected acceleration in Bimzelx growth driven by new indications and atopic dermatitis.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UCBJF:
- UCB price target raised to EUR 200 from EUR 150 at Deutsche Bank
- UCB price target raised to EUR 175 from EUR 160 at Barclays
- UCB upgraded to Outperform from Neutral at Oddo BHF
- UCB price target raised to EUR 150 from EUR 140 at Deutsche Bank
- UCB price target raised to EUR 160 from EUR 150 at Barclays